Cancer drug trial aims to shrink hidden HIV reservoir
NCT ID NCT07481175
Summary
This early-stage study is testing whether adding the cancer drug venetoclax to standard HIV treatment when a person first starts therapy can help. The goal is to see if venetoclax helps the body eliminate more of the cells that hide inactive HIV, potentially reducing the 'reservoir' of virus that persists despite treatment. Researchers will enroll 38 adults new to HIV therapy to check the safety of this approach and measure its effect on the hidden virus.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV-1 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hospital Universitari Germans Trias I Pujol, Department of Infectious Diseases
Badalona, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Infectious Diseases, Q Research
Aarhus, 8200, Denmark
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.